Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs RCEL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RCEL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)
RCEL Overall Winner
6-Pillar Tally: BMRA 1 – 4 RCEL (1 Tie)
Matrix Metrics: BMRA 2 – 8 RCEL
As of Nov 16, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas RCEL carries 53.1/100 (HOLD) at $15.43 (10.3x Forward P/E, -33.9% operating margin).
- Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile RCEL trades in a Markup technical trend (SURGE options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BMRA vs RCEL
BMRA
Biomerica Inc
$1.36
+0.0% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
RCEL
Head-to-Head Winner
Avita Medical, Inc. Common Stock
$15.43
-1.28% 1D
Market Cap
$509.0M
TTM Revenue
$85M
Forward P/E
10.3x
Beta / 30D Vol
1.70β · 72% Vol
Unified Composite Score
53.1
HOLD
Tech 40.0
Fund 50.0
Flow 71.0
Mom 46.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (BMRA 1 – 4 RCEL)
1. Valuation Multiples
RCEL
Forward P/E
N/M
10.3x
Trailing P/E
N/M
10.3x
PEG Ratio
N/M
N/M
EV / Revenue
1.1x
6.4x
2. Growth & Scale
RCEL
Revenue Growth (YoY)
-8.3%
+53.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.3M
$85M
Market Cap
$6.0M
$509.0M
3. Profitability & Quality
RCEL
Gross Margin
0.9%
82.4%
Operating Margin
-125.2%
-33.9%
Net Profit Margin
-115.5%
-42.6%
Return on Equity (ROE)
-113.8%
-1746.3%
4. Balance Sheet & Cash Flow
BMRA
Cash Generation (TTM)
-$3.2M
-$20M
Cash Flow Margin
-73.5%
-23.6%
Net Cash / Leverage
$1.1M Net Cash
$37M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RCEL
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
N/A (N/A)
78.5% (5th %ile)
Put/Call OI Skew
N/A
Thin ADR Chain
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BMRA (2) vs RCEL (8)| Institutional Metric | BMRA | RCEL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.0M | $509.0M | RCEL | |
| Trailing P/E Ratio | N/M | 10.3x | RCEL | |
| Forward P/E Ratio | N/M | 10.3x | RCEL | |
| Revenue Growth (YoY) | -8.3% | +53.1% | RCEL | |
| Operating Margin (TTM) | -125.2% | -33.9% | RCEL | |
| Net Profit Margin | -115.5% | -42.6% | RCEL | |
| Return on Equity (ROE) | -113.8% | -1746.3% | BMRA | |
| 52-Week Range Position | 5% ($1–$3) | 80% ($3–$18) | RCEL | |
| Beta / 30D Volatility | 0.67β · 62% Vol | 1.70β · 72% Vol | BMRA | |
| Unified Institutional Score | 44.5 / 100 (HOLD) | 53.1 / 100 (HOLD) | RCEL | |
| Trailing 12M Revenue (USD) | $4.3M | $85M | Scale | |
| Gross Profit Margin (TTM) | 0.9% | 82.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.1x EV/Rev | N/M PEG · 6.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$3.2M ($1.1M Net Cash) | -$20M ($37M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RCEL +44.82 pp
3M Horizon
RCEL +71.65 pp
6M Horizon
RCEL +307.82 pp
1Y Horizon
RCEL +358.17 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | RCEL Revenue | BMRA Op. Margin | RCEL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $10M | -46.4% | -466.4% | BMRA |
| FY2020 | $10M | $10M | -41.0% | -299.2% | BMRA |
| FY2021 | $10M | $30M | -104.2% | -90.8% | RCEL |
| FY2022 | $20M | $30M | -24.0% | -79.9% | BMRA |
| FY2023 | $10M | $50M | -135.3% | -85.1% | RCEL |
| FY2024 | $10M | $60M | -117.6% | -88.1% | RCEL |
| FY2025 | $10M | $70M | -96.7% | -59.4% | RCEL |
| FY2026 | $0M | N/A | -119.5% | N/A | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RCEL
SURGE
Current IV
78.5%
IV Percentile
5th %ile
Put/Call OI Skew
Thin ADR Chain
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RCEL Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BMRA vs RCEL Key Questions & Quantitative Answers
As of Nov 16, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas RCEL carries 53.1/100 (HOLD) at $15.43 (10.3x Forward P/E, -33.9% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile RCEL trades in a Markup technical trend (SURGE options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RCEL leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.
RCEL screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus RCEL (-1746.3% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, RCEL carries 78.5% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.70β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RCEL vs BMRA · Reverse Pair
RCEL vs SIBN
· Sector Peer
RCEL vs ORIC
· Sector Peer
RCEL vs PROF
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking